Can a single injection tame stubborn multiple sclerosis?

NCT ID NCT07748637

Not yet recruiting Disease control Sponsor: Daishi Tian Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This early-stage trial is testing an investigational injection called GT802 in people with relapsing or refractory multiple sclerosis (MS) — meaning their disease is active despite standard treatments. The study aims to check whether GT802 is safe and to get a first look at whether it might reduce relapses or slow disability. A small group of participants will receive the injection in increasing doses, with close monitoring for side effects and signs of disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GT802 Injection
What this could lead to: If GT802 proves safe and shows signs of easing MS relapses or disability, it could become a new option for people whose MS has not responded to standard treatments.
What could go wrong: This is a very early, small trial focused on safety, so it may not show clear benefit. There are also risks of side effects from the injection itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, MS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS, MS

Contacts and locations

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.